Aspire Biopharma Holdings (ASBP) Cash from Investing Activities (2021 - 2023)
Aspire Biopharma Holdings (ASBP) posted quarterly Cash from Investing Activities of $632968.0 for Q3 2023, up 100.21% quarter-over-quarter from -$294.7 million in Q1 2022.
Aspire Biopharma Holdings (ASBP) Cash from Investing Activities (2021 - 2023) Analysis & Trends
Aspire Biopharma Holdings (ASBP) has reported Cash from Investing Activities for 3 consecutive years, with $632968.0 the latest figure, recorded in Q3 2023.
- In Q3 2023, Cash from Investing Activities changed N/A year-over-year to $632968.0; the TTM figure through Dec 2023 stood at $632968.0 (up 100.21% YoY), while the FY2024 annual figure was $13.8 million, down 95.16% from the prior year.
- Cash from Investing Activities advanced to $632968.0 in Q3 2023 per ASBP's latest filing, from -$294.7 million in the prior quarter.
- Across five years, Cash from Investing Activities topped out at $632968.0 in Q3 2023 and bottomed at -$294.7 million in Q1 2022.
- Historically, Cash from Investing Activities has averaged -$98.0 million across 3 years, with a median of $165955.0 in 2021.
- On a YoY basis, Cash from Investing Activities climbed as much as 177670.73% in 2022 and fell as far as 177670.73% in 2022.
- Aspire Biopharma Holdings' Cash from Investing Activities stood at $165955.0 in 2021, then sank by 177670.73% to -$294.7 million in 2022, then soared by 100.21% to $632968.0 in 2023.
- Business Quant data shows ASBP's Cash from Investing Activities at $632968.0 in Q3 2023, -$294.7 million in Q1 2022, and $165955.0 in Q1 2021.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -45.80 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -92.70 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 329.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | -49.35 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -363.46 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -3.17 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 24.51 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -229.72 Mn |
| 10 | Aspire Biopharma Holdings | 8.30 Mn | -3.86 Mn | -30,086.00 | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2023 | 632,968.00 |
| Sep 30, 2023 | 632,968.00 |
| Mar 31, 2022 | -294.69 Mn |
| Mar 31, 2022 | -294.69 Mn |
| Mar 31, 2021 | 165,955.00 |
| Mar 31, 2021 | 165,955.00 |